Regeneron Announces Investor Webcast at American Society of Hematology 2020 Annual Meeting
TARRYTOWN, N.Y., Nov. 30, 2020 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will host a webcast on Monday, December 7, 2020 at 4:30pm EST. Management will discuss data presented at the American Society of Hematology (ASH) 2020 Annual Meeting as well as provide updates on the Company's broader oncology and hematology portfolio.
Conference Call Information
To access this call, dial (888) 660-6127 (U.S.) or (973) 890-8355 (International), conference ID 7442859. A link to the webcast may be accessed from the 'Investors and Media' page of Regeneron's website at http://investor.regeneron.com/events.cfm. A replay of the conference call and webcast will be archived on the Company's website for at least 30 days.
Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents life-transforming medicines for people with serious diseases. Founded and led for over 30 years by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to eight FDA-approved treatments and numerous product candidates in development, all of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, pain, infectious diseases and rare diseases.
Regeneron is accelerating and improving the traditional drug development process through our proprietary VelociSuite® technologies, such as VelocImmune®, which uses unique genetically-humanized mice to produce optimized fully-human antibodies and bispecific antibodies, and through ambitious research initiatives such as the Regeneron Genetics Center, which is conducting one of the largest genetics sequencing efforts in the world.
For additional information about the company, please visit www.regeneron.com or follow @Regeneron on Twitter.
SOURCE Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals (NASDAQ:REGN) Shareholders Have Enjoyed A 32% Share Price Gain
Yahoo 12/07 05:19 ET
Regeneron's BCMAxCD3 Bispecific Antibody (REGN5458) Shows Deep and Durable Responses in Patients with Heavily-pretreated Multiple Myeloma in Phase 1
PR Newswire 12/05 17:00 ET
Regeneron (REGN) Down 16.4% Since Last Earnings Report: Can It Rebound?
Yahoo 12/05 11:32 ET
3 Best ETF Picks: Megatrends To Invest In Now
Yahoo 12/04 16:49 ET
Don’t Chase the Rebound in Sorrento — It’s Not Worth the Risk
Yahoo 12/04 16:21 ET
Lilly (LLY) to Supply More Doses of COVID-19 Antibody to US
Yahoo 12/03 07:10 ET
Scott+Scott Attorneys at Law LLP Continues Investigation of Regeneron Pharmaceuticals, Inc.’s Directors and Officers for Breach of Fiduciary Duty – REGN
Yahoo 12/02 13:11 ET
Activist Shareholders Press Pfizer, J&J, and Other Pharma Companies on Covid Vaccine Price and Access
Yahoo 12/01 16:55 ET
New Advances in Treating Difficult Blood Cancers From Johnson & Johnson and Others
Yahoo 12/01 14:23 ET
Regeneron (REGN), Sanofi Win EC Nod for Dupixent Label Expansion
Yahoo 11/30 14:39 ET